IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Bram Verstockt(Universitair Ziekenhuis Leuven), Stefania Vetrano(Fondazione Humanitas per la Ricerca), Haim Leibovitzh(Tel Aviv Sourasky Medical Center), Marisol Veny(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Vipul Jairath(Western University), Florian Rieder(Cleveland Clinic), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William A. Faubion(Mayo Clinic in Arizona), Séverine Vermeire(KU Leuven), William J. Sandborn(University of San Diego), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Azucena Salas(Hospital Clínic de Barcelona), Julián Panés(Hospital Clínic de Barcelona), Christopher Ma(University of Calgary), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Saurabh Mehandru(Icahn School of Medicine at Mount Sinai), Niels Vande Casteele(University of California San Diego), Geert D’Haens(Amsterdam University Medical Centers), Mark S. Silverberg(Sinai Health System), Clara Abraham(Yale University), Lars Eckmann(University of San Diego)
Cited by 248
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k